The Transgender Health Association of World Professionals (WPATH) expressed disappointment following the Supreme Court’s decision to uphold Tennessee’s law that prohibits experimental procedures for minors.
In a joint statement with the American Transgender Health Association (USPATH), WPATH asserted that the use of gender-related drugs and surgeries for minors is “evidence-based,” while also contending that laws protecting minors hinder the establishment of such evidence.
“The Supreme Court’s ruling today represents a serious setback for transgender health and human rights across the United States. This ruling will empower states to effectively ban evidence-based, gender-affirming health care for countless transgender and gender-diverse youth and their families,” the organizations stated. “Moreover, it complicates the process of building evidence to support access to such healthcare.”
WPATH cautioned that when governmental barriers are imposed, trained professionals capable of providing this care may inadvertently cause harm.
“Let’s be clear—this healthcare ban stems from stigma, misinformation, and fear, ultimately harming the young people who genuinely need this support,” the statement continued.
WPATH is recognized as a leading authority in transgender healthcare, influencing practices in hospitals in the US, UK, and Canada. The organization also has an impact on health insurance and associations like the American Psychological Association and the American Academy of Pediatrics.
In September 2022, WPATH removed the age requirement from its guidelines regarding interventions that can be similar to chemical castration or gender reassignment procedures.
These procedures, often labeled by supporters as “gender-affirming care,” can involve significant and potentially distressing actions. These include double mastectomies, removal of genitals, facial surgeries, use of puberty blockers, which might result in lifelong infertility, and social transitions such as adopting preferred names and pronouns. The side effects of such treatments can be quite serious and include irreversible changes.
In 2023, Senate Bill 1 was enacted in Tennessee, restricting gender-altering drugs and surgeries for minors, purportedly aiming to protect the rights of minors who might wish to transition. This law has provisions allowing minors or their guardians to sue healthcare providers who do not comply.
Following its passage, a group of transgender minors, their parents, and doctors quickly sought to challenge the law. While some parts of the law prohibiting transgender medications were blocked by a district court, bans on surgeries were upheld. The US Court of Appeals for the Sixth Circuit later affirmed the full law. The Supreme Court reviewed the matter in December 2024 and ultimately confirmed the ruling from the lower court.
The Supreme Court’s decision was 6-3, with dissenting liberal justices arguing against the law’s implications. The court found that Senate Bill 1 does not violate the equal protection clause of the 14th Amendment, countering the assertions made by transgender advocates who took legal action against the state.
In its ruling, the court rejected claims that Tennessee’s law was discriminatory based on gender. Instead, it emphasized that the legislation regulates specific medications and procedures for minors, barring those excluding puberty blockers and cross-sex hormones for addressing gender dysphoria.
The decision sets a precedent for nationwide regulations concerning gender transitions in minors, allowing individual states to formulate their own laws, effectively thwarting legal challenges to similar measures in other states. This is viewed as a step toward safeguarding children from potentially harmful treatments.
Justice Clarence Thomas, in his separate opinion, pointed out multiple shortcomings in the guidance provided by WPATH, criticizing the reliance on insufficient evidence in policymaking that has been influenced by political factors.
He referenced notable controversies surrounding WPATH, including a reported discussion with healthcare professionals about the implications of long-term infertility for a 14-year-old and pressures to eliminate age restrictions for gender transition surgeries from the administration.
“This case serves as a clear reminder that in politically charged discussions where scientific evidence is ambiguous, courts should not simply defer to self-identified experts,” Thomas remarked.
WPATH is generally associated with the Biden administration but has faced criticism from the current Trump administration. In January, President Trump signed an executive order aimed at “Protecting children from chemical and surgical mutilation,” dismissing WPATH’s guidance as “junk science.”
“The significant harm to children resulting from chemical and surgical amendments is often fueled by guidance from the World Professional Association (WPATH) that lacks scientific credibility,” the executive order stated.
